



Round Table Report

8 February 2021

For restricted use

This report summarizes the ECDC daily roundtable discussion and provides update on threats detected and monitored by Epidemic Intelligence.

Active threat

COVID-19 associated with SARS-CoV-2 – multi-country (world) – 2019-2021

Other news:

According to media [reports](#), the use of the AstraZeneca-Oxford COVID-19 vaccine has been halted in South Africa after evidence indicating that in the phase 3 clinical trial participants the AstraZeneca-Oxford vaccine showed minimal efficacy in preventing mild and moderate illness caused by the B.1.351 variant (first detected in South Africa). It is currently unknown if it prevents against severe disease and hospitalisation since study participants were mainly young individuals not prone to severe disease. In addition, plans are being made for South African health care workers to be inoculated with the Johnson & Johnson COVID-19 vaccine, which seems to exhibit a better efficacy in preventing severe cases and hospitalisations caused by the B.1.351 variant, as part of the ongoing phase 3 clinical trial in support of its authorization.

SARS-CoV-2 variants - Multi-country (World) - 2020-2021

As of 08 February 2021, according to media and official sources, the variant **VOC 202012/01** has been identified in 77 countries. Since its identification and as of 08 February 2021, approximately 50 000 cases have been identified.

In the EU/EEA, around 4 100 cases have been identified in 28 countries: Denmark (1 076), [5.1.2a](#) (391), France (384), Spain (324), Netherlands (323), Ireland (276), Sweden (250), Greece (205), Italy (162), Austria (140), Portugal (114), Finland (88), [5.1.2a](#) (77), Norway (65), Iceland (37), Slovakia (37), Bulgaria (33), Luxembourg (32), Romania (20), Czechia (13), Cyprus (12), Poland (9), Hungary (5), Latvia (5), Malta (3), Liechtenstein (1), Lithuania (1) and Slovenia (1).

Outside the EU/EEA, approximately 45 900 cases have been identified in 49 countries: United Kingdom (44 101), United States of America (611), Switzerland (206), Turkey (196), India (150), [5.1.2a](#) (147), Australia (71), Jordan (40), Singapore (38), Japan (34), South Korea (27), New Zealand (26), Canada (24), United Arab Emirates (23), Chile (20), Philippines (17), Brazil (15), Vietnam (12), Saudi Arabia (10), Nigeria (7), Taiwan (7), [5.1.2a](#) (6), Ecuador (6), Iran (4), Jamaica (4), Thailand (4), Bangladesh (3), Gambia (3), Nepal (3), Pakistan (3), Russia (3), [5.1.2e](#) (3), Malaysia (2), Argentina (1), Dominican Republic (1), Georgia (1), Kuwait (1), Lebanon (1), Mexico (1), Morocco (1), North Macedonia (1), Oman (1), Panama (1), Peru (1), Senegal (1), Serbia (1), South Africa (1), Sri Lanka (1) and Trinidad and Tobago (1).

As of 08 February 2021, according to media and official sources, the variant **501.V2** has been identified in 37 countries. Since its identification and as of 08 February 2021, approximately 990 cases have been identified.

1/2

European Centre for Disease Prevention and Control (ECDC)

Postal address: ECDC 169 73 Solna, Sweden
Visiting address: Gustav III:s Boulevard 40, Solna, Sweden
ecdc.europa.eu

Epidemic Intelligence duty email: 5.1.5@ecdc.europa.eu

In the EU/EEA, around 220 cases have been identified in 15 countries: Austria (75), France (40), 5.1.2a (33), Netherlands (22), 5.1.2a (17), Ireland (9), Denmark (5), Finland (2), Luxembourg (2), Spain (2), Greece (1), Italy (1), Norway (1), Portugal (1) and Sweden (1).

Outside the EU/EEA, approximately 780 cases have been identified in 22 countries: South Africa (549), United Kingdom (112), Mozambique (19), Israel (12), Canada (11), Switzerland (11), Australia (10), Botswana (10), New Zealand (7), South Korea (7), United Arab Emirates (5), United States of America (5), Japan (4), 5.1.2a (2), Kenya (2), Turkey (2), Brazil (1), Cuba (1), Panama (1), Serbia (1), Taiwan (1) and Zambia (1).

As of 08 February 2021, according to media and official sources, the variant P.1 has been identified in 14 countries. Since its identification and as of 08 February 2021, approximately 90 cases have been identified.

In the EU/EEA, around 20 cases have been identified in 4 countries: France (4), Italy (4), Netherlands (2) and 5.1.2a (1).

Outside the EU/EEA, approximately 80 cases have been identified in 10 countries: Brazil (51), United Kingdom (9), South Korea (5), Japan (4), United States of America (3), Canada (1), Colombia (1), Faroe Islands (1), Peru (1) and Turkey (1).

Risk assessment under production

Joint ECDC and EFSA rapid outbreak assessment to be produced on Salmonella Enteritidis contamination in poultry products from Poland to be published 18 February 2021.

The Round Table Report contains information that could be considered sensitive or is still under verification. Its distribution is restricted to intended users only.

Participants

Senior Management: -

EI and Response Head of Section: -

Duty Officers:

24/7: -

Threat Detection: -

Rapid Assessment and Outbreaks: -

Communication: -

Representative of:

Epidemic Intelligence: -

Response: -

Vaccine Preventable Diseases: -

Emerging and Vector-borne Diseases: -

Food and Water-borne Diseases: -

Influenza: -

Microbiology Coordination: -